Work

Prognostic value of the lung immune prognostic index in patients with untreated advanced renal cell carcinoma (aRCC) receiving nivolumab plus ipilimumab (N+I) or sunitinib (SUN) in the CheckMate 214 trial.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.4538

Authors: Lucia Carril-Ajuria, Robert J. Motzer, Nizar M. Tannir, David F. McDermott, Hans J. Hammers, Elizabeth R. Plimack, Frede Donskov, Brian I. Rini, Ruiyun Jiang, Chung-Wei Lee, Heshani Desilva, Laurence Albiges

Institutions: Institut Gustave Roussy, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, The University of Texas Southwestern Medical Center, Fox Chase Cancer Center, Aarhus University Hospital, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Bristol-Myers Squibb (United States)

Language: English

Topic: Inflammatory Biomarkers in Disease Prognosis

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4286295774

Cites:

Cited by: 4

Related to: 10